Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer

Bardia, A; Kaklamani, V; Wilks, S; Weise, A; Richards, D; Harb, W; Osborne, C; Wesolowski, R; Karuturi, M; Conkling, P; Bagley, RG; Wang, YM; Conlan, MG; Kabos, P

Bardia, A (corresponding author), Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.

JOURNAL OF CLINICAL ONCOLOGY, 2021; 39 (12): 1360

Abstract

PURPOSEThis phase I study (RAD1901-005; NCT02338349) evaluated elacestrant, an investigational oral selective estrogen receptor degrader (SERD), in he......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索